InVivo Therapeutics Holdings Corporation
NVIV · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.02 | 0.01 | 0.00 |
| FCF Yield | -294.73% | -58.69% | -171.25% | -466.54% |
| EV / EBITDA | 1.16 | 0.26 | 1.47 | 0.29 |
| Quality | ||||
| ROIC | -61.70% | -50.70% | -44.80% | -171.04% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.00 | 0.89 | 1.05 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -19.16% | 6.73% | 7.27% | 16.57% |
| Safety | ||||
| Net Debt / EBITDA | 1.51 | 1.86 | 2.11 | 0.50 |
| Interest Coverage | -70.53 | 0.00 | -478.79 | -45.26 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -506.08 | -593.62 | -533.63 | -1,067.80 |